Targovax ASA (0RIS) AI Stock Analysis

2 Followers

Targovax ASA

(LSE:0RIS)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Negative Factors

Targovax ASA (0RIS) vs. iShares MSCI United Kingdom ETF (EWC)

Market Cap: NOK 2.81B
Dividend Yield: ―
Average Volume (3M): 15.80K
Price to Earnings (P/E): -25.0
Beta (1Y): -1.22
Revenue Growth: ―
EPS Growth: -415.85%
Country: UK
Employees: 10
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Targovax ASA Business Overview & Revenue Model

Company Description

Circio Holding ASA, a biotechnology firm based in Oslo, Norway, and founded in 2010, specializes in the development of advanced circular RNA and immunotherapy treatments. Among its key innovations is TG01, a cancer vaccine aimed at specific driver mu...

Targovax ASA Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

GB:0RIS against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:AZN	80Outperform	GBP 216.04B	26.11	22.31%	1.72%	4.55%	14.19%
GB:GSK	69Neutral	GBP 75.77B	17.50	24.64%	3.60%	4.28%	-19.93%
GB:4BB	52Neutral	GBP 82.07M	-4.57	-316.73%	―	-56.10%	-16.77%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

* Healthcare Sector Average

Performance Comparison

GB:0RIS and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
GB:0RIS	Targovax Asa	9.88	8.98	999.00%
GB:4BB	4basebio UK Societas	530.00	-255.00	-32.48%
GB:GSK	GlaxoSmithKline plc (UK)	1890.00	178.90	10.46%
GB:AZN	AstraZeneca plc	13930.00	1024.52	7.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Targovax ASA AI Stock Analysis